{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:57:31Z","timestamp":1789822651723,"version":"4.0.1"},"reference-count":99,"publisher":"Compuscript, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zoonoses"],"abstract":"<jats:p>Vaccines are among the most effective medical countermeasures against infectious diseases. The emergence of the Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred scientific strategies to fight against the disease. Since 2020, in response to the pandemic, many vaccines based on different platforms have been under development, among which mRNA, adenoviral vectors, and subunit vaccines have been clinically approved for use in humans. These first-generation COVID-19 vaccines largely target the viral spike (S) protein and are aimed at eliciting potent neutralizing antibodies. With the emergence of SARS-CoV-2 variants, particularly the highly transmissible Omicron strains, S-based vaccine strategies have faced a continuing challenge of strong immune escape by variants. The coronavirus nucleocapsid (N) protein is a viral protein that induces strong T-cell immunity and is more conserved than S protein across different SARS-CoV-2 variants. Inclusion of N protein in the development of COVID-19 vaccines has been reported. Here, we briefly review and discuss COVID-19, current S-protein-based vaccine strategies, the immunobiology of N protein in SARS-CoV-2 host immunity, and next-generation vaccine strategies involving N protein to combat current and emerging SARS-CoV-2 variants.<\/jats:p>","DOI":"10.15212\/zoonoses-2023-0003","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T23:10:23Z","timestamp":1681859423000},"source":"Crossref","is-referenced-by-count":8,"title":["Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein"],"prefix":"10.15212","volume":"3","author":[{"given":"Srinivasa Reddy","family":"Bonam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5858","published-online":{"date-parts":[[2023]]},"reference":[{"key":"r1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"N Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"r2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"key":"r3","volume":"Vol. 2023","author":"World Health Organization","year":"2020"},{"key":"r4","author":"World Health Organization","year":"2022"},{"issue":"2","key":"r5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s15010-020-01531-3","article-title":"Epidemiology of SARS-CoV-2","volume":"49","author":"B Salzberger","year":"2021","journal-title":"Infection"},{"issue":"1","key":"r6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044640","article-title":"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies","volume":"11","author":"BG Pijls","year":"2021","journal-title":"BMJ Open"},{"key":"r7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/v13030452","article-title":"A comparative systematic review of COVID-19 and influenza","volume":"13","author":"M Osman","year":"2021","journal-title":"Viruses"},{"key":"r8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"WJ Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"r9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13098-020-00586-4","article-title":"Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis","volume":"12","author":"B de Almeida-Pititto","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"r10","first-page":"794","article-title":"Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease","volume":"2","author":"N Saksena","year":"2022","journal-title":"Explor Immunol"},{"key":"r11","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101051","article-title":"Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections","volume":"36","author":"SR Bonam","year":"2021","journal-title":"Nano Today"},{"key":"r12","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.581726","article-title":"Epigenetic lens to visualize the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in COVID-19 pandemic","volume":"12","author":"N Saksena","year":"2021","journal-title":"Front Genet"},{"key":"r13","first-page":"61","article-title":"Immunopathogenesis of severe acute respiratory syndrome coronavirus-2: evolving knowledge and its current status","volume":"1","author":"N Saksena","year":"2021","journal-title":"Explor Immunol"},{"key":"r14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"H Xu","year":"2020","journal-title":"Int J Oral Sci"},{"key":"r15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"CB Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"r16","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"DC Fajgenbaum","year":"2020","journal-title":"New Engl J Med"},{"key":"r17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.561674","article-title":"Celebrex adjuvant therapy on coronavirus disease 2019: an experimental study","volume":"11","author":"W Hong","year":"2020","journal-title":"Front Pharmacol"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202008.0519.v1","article-title":"Rapid clinical recovery from severe COVID-19 with high dose famotidine and high dose celecoxib adjuvant therapy","author":"K Tomera","year":"2020","journal-title":"Preprints"},{"key":"r19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76781-0","article-title":"The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19)","volume":"10","author":"A Arcanjo","year":"2020","journal-title":"Sci Rep"},{"key":"r20","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103071","article-title":"The autonomic aspects of the post-COVID19 syndrome","volume":"21","author":"A Dotan","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"7477","key":"r21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"XY Ge","year":"2013","journal-title":"Nature"},{"key":"r22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","article-title":"Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations","volume":"6","author":"YN Cao","year":"2020","journal-title":"Cell Discov"},{"key":"r23","article-title":"A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"P Kakodkar","year":"2020","journal-title":"Cureus"},{"key":"r24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nri2802","article-title":"Immunity and immunopathology to viruses: what decides the outcome?","volume":"10","author":"BT Rouse","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"r25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"SR Bonam","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"r26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.immuni.2007.08.012","article-title":"Innate recognition of viruses","volume":"27","author":"A Pichlmair","year":"2007","journal-title":"Immunity"},{"key":"r27","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.immuni.2021.11.016","article-title":"Antigenic drift: understanding COVID-19","volume":"54","author":"JW Yewdell","year":"2021","journal-title":"Immunity"},{"issue":"7923","key":"r28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"2","key":"r29","doi-asserted-by":"crossref","first-page":"e00245","DOI":"10.1128\/mSystems.00245-20","article-title":"2019 Novel coronavirus (COVID-19) pandemic: built environment considerations to reduce transmission","volume":"5","author":"L Dietz","year":"2020","journal-title":"mSystems"},{"key":"r30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"B Korber","year":"2020","journal-title":"Cell"},{"key":"r31","volume":"Vol. 2022","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"r32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"WT Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"19","key":"r33","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/j.cell.2022.08.010","article-title":"Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests","volume":"185","author":"F Frank","year":"2022","journal-title":"Cell"},{"issue":"9","key":"r34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s10096-020-03899-4","article-title":"The genetic sequence, origin, and diagnosis of SARS-CoV-2","volume":"39","author":"H Wang","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"r35","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor","volume":"11","author":"J Yang","year":"2020","journal-title":"Nat Commun"},{"key":"r36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Z Andreadakis","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"r37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"F Krammer","year":"2020","journal-title":"Nature"},{"key":"r38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"N Chaudhary","year":"2021","journal-title":"Nat Rev Drug Dis"},{"key":"r39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"NC Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"r40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","article-title":"A comprehensive review of the global efforts on COVID-19 vaccine development","volume":"7","author":"Y Li","year":"2021","journal-title":"ACS Cent Sci"},{"key":"r41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines - immunity, variants, boosters","volume":"387","author":"DH Barouch","year":"2022","journal-title":"N Engl J Med"},{"key":"r42","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.ymthe.2022.08.020","article-title":"The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs","volume":"30","author":"M Shah","year":"2022","journal-title":"Mol Ther"},{"key":"r43","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"SA Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"r44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 vaccines and the growing threat of viral variants","volume":"325","author":"JP Moore","year":"2021","journal-title":"JAMA"},{"key":"r45","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"W Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"r46","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"D Zhou","year":"2021","journal-title":"Cell"},{"issue":"9","key":"r47","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"WF Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"7898","key":"r48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"r49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"D Planas","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"r50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"L Liu","year":"2022","journal-title":"Nature"},{"issue":"12","key":"r51","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"P Tang","year":"2021","journal-title":"Nat Med"},{"issue":"16","key":"r52","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"r53","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1128\/JCM.42.11.5309-5314.2004","article-title":"Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus","volume":"42","author":"Y He","year":"2004","journal-title":"J Clin Microbiol"},{"key":"r54","doi-asserted-by":"crossref","first-page":"e01925","DOI":"10.1128\/JVI.01925-19","article-title":"Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle","volume":"94","author":"Y Cong","year":"2020","journal-title":"J Virol"},{"key":"r55","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1038\/s41467-020-19843-1","article-title":"Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates","volume":"11","author":"A Savastano","year":"2020","journal-title":"Nat Commun"},{"key":"r56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009100","article-title":"Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein","volume":"16","author":"DC Dinesh","year":"2020","journal-title":"PLoS Path"},{"key":"r57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41467-020-20768-y","article-title":"The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein","volume":"12","author":"S Lu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"r58","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41467-021-21953-3","article-title":"The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA","volume":"12","author":"J Cubuk","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"r59","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/jacsau.1c00139","article-title":"Multiple roles of SARS-CoV-2 N protein facilitated by proteoform-specific interactions with RNA, host proteins, and convalescent antibodies","volume":"1","author":"CA Lutomski","year":"2021","journal-title":"JACS Au"},{"issue":"662","key":"r60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq1945","article-title":"Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models","volume":"14","author":"RL Hajnik","year":"2022","journal-title":"Sci Transl Med"},{"key":"r61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2013.12.009","article-title":"The SARS coronavirus nucleocapsid protein \u2013 Forms and functions","volume":"103","author":"Ck Chang","year":"2014","journal-title":"Antiviral Res"},{"issue":"6","key":"r62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/biology10060454","article-title":"Viewing SARS-CoV-2 nucleocapsid protein in terms of molecular flexibility","volume":"10","author":"T Matsuo","year":"2021","journal-title":"Biology"},{"key":"r63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbrc.2021.01.073","article-title":"The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients","volume":"543","author":"Smits","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"r64","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"L Guo","year":"2022","journal-title":"Lancet Microbe"},{"issue":"7","key":"r65","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"A Grifoni","year":"2020","journal-title":"Cell"},{"issue":"7821","key":"r66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"N Le Bert","year":"2020","journal-title":"Nature"},{"issue":"6","key":"r67","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"L Ni","year":"2020","journal-title":"Immunity"},{"issue":"5","key":"r68","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1128\/JCM.42.5.2306-2309.2004","article-title":"Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia","volume":"42","author":"Woo","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"5","key":"r69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.immuni.2021.04.006","article-title":"CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses","volume":"54","author":"KE Lineburg","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"r70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.immuni.2021.04.009","article-title":"CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity","volume":"54","author":"Nguyen","year":"2021","journal-title":"Immunity"},{"issue":"11","key":"r71","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Y Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"r72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"P Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"13","key":"r73","doi-asserted-by":"crossref","first-page":"e00647","DOI":"10.1128\/JVI.00647-20","article-title":"The nucleocapsid protein of SARS-CoV-2: a target for vaccine development","volume":"94","author":"NK Dutta","year":"2020","journal-title":"J Virol"},{"issue":"13","key":"r74","article-title":"Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post\u2013COVID-19 syndrome","volume":"7","author":"X Jia","year":"2022","journal-title":"JCI Insight"},{"issue":"2","key":"r75","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster","volume":"29","author":"C Kurhade","year":"2023d","journal-title":"Nat Med"},{"key":"r76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2019.113806","article-title":"Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design","volume":"277","author":"A Sheikh","year":"2020","journal-title":"J Virol Methods"},{"issue":"1","key":"r77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.imlet.2008.03.003","article-title":"Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine","volume":"118","author":"NK Dutta","year":"2008","journal-title":"Immunol Lett"},{"issue":"1","key":"r78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-023-01968-6","article-title":"The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics","volume":"20","author":"W Wu","year":"2023","journal-title":"Virol J"},{"issue":"10","key":"r79","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"T Dangi","year":"2021","journal-title":"Cell Rep"},{"issue":"23","key":"r80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162282","article-title":"Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody","volume":"132","author":"T Dangi","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"r81","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"WE Matchett","year":"2021","journal-title":"J Immunol"},{"issue":"5","key":"r82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268434","article-title":"Immunization with SARS-CoV-2 nucleocapsid protein triggers a pulmonary immune response in rats","volume":"17","author":"Silva","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"r83","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24479","article-title":"Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine","volume":"36","author":"W Feng","year":"2022","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"r84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/vaccines9050520","article-title":"A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques","volume":"9","author":"PE Harris","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"r85","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"F Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"r86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"F Chiuppesi","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"4","key":"r87","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"F Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"issue":"72","key":"r88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo0226","article-title":"A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection","volume":"7","author":"NK Routhu","year":"2022","journal-title":"Sci Immunol"},{"issue":"5","key":"r89","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","article-title":"Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2","volume":"185","author":"S Afkhami","year":"2022","journal-title":"Cell"},{"issue":"1","key":"r90","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94364-5","article-title":"Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice","volume":"11","author":"A Rice","year":"2021","journal-title":"Sci Rep"},{"key":"r91","article-title":"Prime hAd5 spike + nucleocapsid vaccination induces ten-fold increases in mean T-cell responses in phase 1 subjects that are sustained against spike variants","author":"P Sieling","year":"2021","journal-title":"medRxiv"},{"key":"r92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1025500","article-title":"Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins","volume":"13","author":"KL O\u2019Donnell","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"r93","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215821","article-title":"A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells","volume":"14","author":"S Appelberg","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"3","key":"r94","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"JY Ahn","year":"2022","journal-title":"Lancet Microbe"},{"issue":"22","key":"r95","article-title":"Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates","volume":"7","author":"SH Hong","year":"2021","journal-title":"Sci Adv"},{"issue":"6","key":"r96","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"J Zhao","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"r97","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1172\/JCI63689","article-title":"Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms","volume":"122","author":"KK McKinstry","year":"2012","journal-title":"J Clin Invest"},{"issue":"14","key":"r98","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMc2210546","article-title":"Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"P Qu","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"r99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204336119","article-title":"The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2","volume":"119","author":"JP Townsend","year":"2022","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Zoonoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/scienceopen.com\/document_file\/1ce1da0e-befc-4d63-b662-6cf01655702c\/ScienceOpen\/Zoonoses20230003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.15212\/ZOONOSES-2023-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T04:10:26Z","timestamp":1752120626000},"score":1,"resource":{"primary":{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.15212\/ZOONOSES-2023-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.15212\/zoonoses-2023-0003","relation":{},"ISSN":["2737-7466","2737-7474"],"issn-type":[{"value":"2737-7466","type":"print"},{"value":"2737-7474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}